Delorme E, Alexander P. Treatment of primary fibrosarcoma in the rat with immune lymphocytes. The Lancet. 1964;284(7351):117–20.

Article  Google Scholar 

Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149(3):960–8.

Article  CAS  PubMed  Google Scholar 

Oldham RA, Medin JA. Practical considerations for chimeric antigen receptor design and delivery. Expert Opin Biol Ther. 2017;17(8):961–78.

Article  CAS  PubMed  Google Scholar 

Morgan MA, Büning H, Schambach A. Use of cell and genome modification technologies to generate improved “off-the-shelf” CAR T and CAR NK cells. Front Immunol. 2020;11: 557760.

Article  Google Scholar 

Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018;9: 330897.

Article  Google Scholar 

Herrera L, Santos S, Vesga MA, Carrascosa T, Garcia-Ruiz JC, Pérez-Martínez A, et al. The race of CAR therapies: CAR-NK cells for fighting B-cell hematological cancers. Cancers. 2021;13(21):5418.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell. 2020;181(1):46–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discovery. 2020;19(3):200–18.

Article  CAS  PubMed  Google Scholar 

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno C, Haynie C, Johnson A, Weber K. 2022 Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. Biomedicines. 10, 1493. s Note: MDPI stays neutral with regard to jurisdictional claims in published 2022.

Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11:1–9.

Article  Google Scholar 

Guedan S, Calderon H, Posey AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Therapy-Methods & Clinical Development. 2019;12:145–56.

Article  CAS  Google Scholar 

Kim DW, Cho J-Y. Recent advances in allogeneic CAR-T cells. Biomolecules. 2020;10(2):263.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9.

Article  CAS  PubMed  Google Scholar 

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci. 1989;86(24):10024–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3(1):35–45.

Article  CAS  PubMed  Google Scholar 

Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas. Mol Ther. 2018;26(12):2727–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22(2):57–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomasik J, Jasiński M, Basak GW. Next generations of CAR-T cells-new therapeutic opportunities in hematology? Front Immunol. 2022;13:1034707.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333–47.

Article  CAS  PubMed  Google Scholar 

Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Therapy Methods & Clinical Development. 2017;4:92–101.

Article  CAS  Google Scholar 

Esfahani K, Roudaia L, Na B, Del Rincon S, Papneja N, Miller W. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(s2):87–97.

Article  Google Scholar 

Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood J Am Soc Hematol. 2015;125(26):4017–23.

CAS  Google Scholar 

DeVita VT Jr, Chu E. A history of cancer chemotherapy. Can Res. 2008;68(21):8643–53.

Article  CAS  Google Scholar 

Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaître F, et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021;6(57):4344.

Article  Google Scholar 

Qin VM, D’Souza C, Neeson PJ, Zhu JJ. Chimeric antigen receptor beyond CAR-T cells. Cancers. 2021;13(3):404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. J Cellular Immunotherapy. 2016;2(2):59–68.

Article  Google Scholar 

Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med. 2015;240(8):1087–98.

Article  CAS  Google Scholar 

Park JR, DiGiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825–33.

Article  CAS  PubMed  Google Scholar 

Imai C, Mihara K, Andreansky M, Nicholson I, Pui C, Geiger T, et al. Chimeric receptors with 4–1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18(4):676–84.

Article  CAS  PubMed  Google Scholar 

Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Translational Med. 2011;3(95):95ra73-95ra73.

Article  CAS  Google Scholar 

Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol. 2001;167(11):6123–31.

Article  CAS  PubMed  Google Scholar 

Asmamaw Dejenie T, Tiruneh G, Medhin M, Dessie Terefe G, Tadele Admasu F, Wale Tesega W, Chekol AE. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccin Immunotherapeutics. 2022;18(6):2114254.

Article  Google Scholar 

Schubert M-L, Schmitt A, Neuber B, Hückelhoven-Krauss A, Kunz A, Wang L, et al. Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients. Blood. 2019;134:51.

Article  Google Scholar 

Maakaron JE, Hu M, El Jurdi N. Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. Bmj. 2022. https://doi.org/10.1136/bmj-2021-068956.

Article  Google Scholar 

Jung SM, Kim W-U. Targeted immunotherapy for autoimmune disease. Immune Network. 2022. https://doi.org/10.4110/in.2022.22.e9.

Article  PubMed  PubMed Central  Google Scholar 

Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021;18(8):1896–903.

Article  CAS  PubMed  Google Scholar 

Kansal R, Richardson N, Neeli I, Khawaja S, Chamberlain D, Ghani M, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Translational Med. 2019;11(482):eaav1648.